Beam Therapeutics Inc. (BEAM)

NASDAQ • Healthcare

$24.5

+$0.1 (+0.5%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$25

Day Range$24.21 - $25.48

Avg. Volume (3M)2M

Market Cap$2.5B

52 Week Range

$20.23$38.26

Next EarningsIn 30 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$490K100%

Gross Profitminus cost of goods$490K100%

Fundamentals & Financials

Revenue (TTM)

$156M

Net Income (TTM)

-$85.4M

EPS (TTM)

-$0.82

ROA (TTM)

-6.16%

Current Ratio

14.57

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+3.8%Q3 2025-$1

-12.2%Q4 2025-$1.1

+91.2%Q1 2026-$0.1

-4.6%Q2 2026-$0.91

-6.3%Q3 2026-$1.18

Nov 3

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -6.3%

Beam Therapeutics’ bottom line missed expectations as EPS of -$1.18 trailed the -$1.11 estimate by -$0.07, with the company’s results for the second fiscal quarter of 2026 reported August 4, 2026 also showing a wider loss versus a year ago. Net income was -$122.7 million, down 19.9% from -$102.3 million a year earlier, and operating income came in at -$126.6 million as the company continued investing across its gene-editing pipeline, including programs such as BEAM-101, BEAM-102, BEAM-201, and BEAM-301. Operating cash flow was negative $66.1 million for the quarter. Compared with the year-ago period, EPS moved to -$1.18 from -$1.00 (down 18.0% year over year). For the next period, consensus calls for EPS of -$1.16 on revenue of $8.7 million.

View full earnings history

About Beam Therapeutics Inc.

Beam Therapeutics Inc. develops gene-editing medicines in biotechnology, focused on precise genetic remedies for severe diseases. The company, which trades on NASDAQ as BEAM, recorded $139.7 million in revenue in FY2025. Its work centers on engineered therapies for blood disorders and other serious conditions, with operations based in the United States.

Name

Beam Therapeutics Inc.

CEO

John Evans

Website

www.beamtx.com

Industry

Healthcare

Year Founded

2017

Employees

540

Today's Snapshot

AI-generated

BEAM closed slightly higher at 24.50, in line with a flat sector. Beam sued gene-editing rivals YolTech and SeraphaBio over alleged trade-secret theft.

Trading Volume

Below 10d avg (1.7M)

1.4M

vs S&P 500 Today

Moderate Underperformance

-0.33%

Updated: October 2, 2026 at 20:21 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

BEAM is trading essentially at its classic pivot, but the technical picture leans negative. Momentum measures are subdued with an RSI in the low 40s and a slightly negative MACD, while short- and medium-term moving averages sit above the current price and the 200-day levels remain notably higher, underscoring longer-term weakness. Trend strength is limited, as ADX is below the mid-20s, yet volatility is elevated by an ATR near five to six percent, and OBV shows buying interest despite the price softness. Technical takeaway: Sell.

All signals